Literature DB >> 11408815

Distant metastases from nasopharyngeal cancer.

F Chiesa1, F De Paoli.   

Abstract

Undifferentiated carcinoma is the most frequent nasopharyngeal cancer; it has a typical pathognomonic histological pattern, a close relationship to Epstein-Barr virus (EBV), a peculiar natural history and a good prognosis. It has an early tendency to locally spread to the parapharyngeal space. Nodal involvement is highly frequent (70-90%) and bulky regardless of the size of the primary. Literature reports up to 11% distant metastases at presentation and up to 87% at autoptic studies. Pretreatment work-up should include: personal history, clinical and fiberscopic examination, magnetic resonance imaging (MRI) or computed tomography (CT) scan of the base of the skull and neck, histology of the primary and cytology of neck lumps, bone marrow aspiration and biopsy, and EBV serological profile. Clinical and pathological factors predicting possible distant spread are primary tumor and node extension, and treatment failure. Up to now no reliable predictive biological markers have been identified. After treatment, distant metastases are found in about 30% of patients within 5 years and generally have a bad prognosis. Metastatic nodes above the clavicle, in absence of locoregional failure, aggressively treated with chemoradiotherapy, have a disease-free survival longer than 5 years. The following is the suggested posttreatment work-up for early diagnosis of these salvageable patients: clinical and fiberscopic evaluation every 3 months for 2 years and later on every 6 months; skull base and neck MRI or CT scan, and chest CT scan at 6, 12, 18, 24, 36, 48 and 60 months; EBV serological evaluation. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408815     DOI: 10.1159/000055743

Source DB:  PubMed          Journal:  ORL J Otorhinolaryngol Relat Spec        ISSN: 0301-1569            Impact factor:   1.538


  18 in total

Review 1.  Diagnosis and management of neck metastases from an unknown primary.

Authors:  L Calabrese; B A Jereczek-Fossa; J Jassem; A Rocca; R Bruschini; R Orecchia; F Chiesa
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-02       Impact factor: 2.124

2.  Prognostic stratification of patients with metastatic nasopharyngeal carcinoma using a clinical and biochemical scoring system.

Authors:  Jeremy Chee; Kwok Seng Loh; Ivan Tham; Francis Ho; Lea Choung Wong; Chee Seng Tan; Boon Cher Goh; Chwee Ming Lim
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-28       Impact factor: 4.553

3.  Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma.

Authors:  Ying Jin; Yan-Xia Shi; Xiu-Yu Cai; Xi-Ya Xia; Yu-Chen Cai; Ye Cao; Wei-Dong Zhang; Wei-Han Hu; Wen-Qi Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-10       Impact factor: 4.553

4.  Effects of silencing S100A8 and S100A9 with small interfering RNA on the migration of CNE1 nasopharyngeal carcinoma cells.

Authors:  Lin-Lin Yan; Yuan-Jiao Huang; Xiang Yi; Xue-Min Yan; Yan Cai; Qin He; Zi-Jian Han
Journal:  Oncol Lett       Date:  2015-03-31       Impact factor: 2.967

5.  Zoledronic acid combined with chemotherapy bring survival benefits to patients with bone metastases from nasopharyngeal carcinoma.

Authors:  Ying Jin; Xin An; Yu Chen Cai; Ye Cao; Xiu Yu Cai; Qing Xia; Yu Ting Tan; Wen Qi Jiang; Yan Xia Shi
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-13       Impact factor: 4.553

6.  Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma.

Authors:  Liang Zhao; Yizhen Pang; Hua Zheng; Chengkun Han; Jianwei Gu; Long Sun; Hua Wu; Sangang Wu; Qin Lin; Haojun Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-01       Impact factor: 9.236

Review 7.  Metastatic disease in head & neck oncology.

Authors:  Paolo Pisani; Mario Airoldi; Anastasia Allais; Paolo Aluffi Valletti; Mariapina Battista; Marco Benazzo; Roberto Briatore; Salvatore Cacciola; Salvatore Cocuzza; Andrea Colombo; Bice Conti; Alberto Costanzo; Laura Della Vecchia; Nerina Denaro; Cesare Fantozzi; Danilo Galizia; Massimiliano Garzaro; Ida Genta; Gabriela Alejandra Iasi; Marco Krengli; Vincenzo Landolfo; Giovanni Vittorio Lanza; Mauro Magnano; Maurizio Mancuso; Roberto Maroldi; Laura Masini; Marco Carlo Merlano; Marco Piemonte; Silvia Pisani; Adriele Prina-Mello; Luca Prioglio; Maria Gabriella Rugiu; Felice Scasso; Agostino Serra; Guido Valente; Micol Zannetti; Angelo Zigliani
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-04       Impact factor: 2.124

8.  Serum alkaline phosphatase predicts survival outcomes in patients with skeletal metastatic nasopharyngeal carcinoma.

Authors:  Ying Jin; Mei-Qin Yuan; Jun-Qing Chen; Yi-Ping Zhang
Journal:  Clinics (Sao Paulo)       Date:  2015-04       Impact factor: 2.365

9.  The Glasgow Prognostic Score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma.

Authors:  Cui Chen; Peng Sun; Qiang-sheng Dai; Hui-wen Weng; He-ping Li; Sheng Ye
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

10.  Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study.

Authors:  Wang Li; Lu-Jun Shen; Tao Chen; Xu-Qi Sun; Ying Zhang; Ming Wu; Wan-Hong Shu; Chen Chen; Chang-Chuan Pan; Yun-Fei Xia; Pei-Hong Wu
Journal:  Chin J Cancer       Date:  2016-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.